Improving cancer treatment for gliomas by targeting DNA damage response
Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomas
['FUNDING_CAREER'] · YALE UNIVERSITY · NIH-10923883
This study is looking at how blocking certain proteins that help repair DNA can make immune treatments work better for patients with a specific type of brain cancer called gliomas that have IDH mutations, with the hope of improving their treatment outcomes.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10923883 on ClinicalTrials.gov |
What this research studies
This research investigates how inhibiting specific proteins involved in DNA damage response can enhance the effectiveness of immune therapies for gliomas with IDH mutations. The approach involves using pre-clinical models to understand the relationship between DNA repair mechanisms and the immune response to tumors. By combining these therapies, the goal is to improve patient outcomes in treating this aggressive form of brain cancer. The research will also involve advanced training in cancer biology and immunology to ensure a comprehensive understanding of the treatment landscape.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with IDH mutant gliomas who may benefit from innovative cancer therapies.
Not a fit: Patients with gliomas that do not have IDH mutations or those with other types of brain tumors may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with IDH mutant gliomas, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results in targeting DNA repair pathways to enhance cancer treatment, indicating that this approach has potential for success.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VASQUEZ, JUAN C — YALE UNIVERSITY
- Study coordinator: VASQUEZ, JUAN C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Biology, Cancer Induction, Cancer Treatment